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Background: The role of low-intensity pulsed ultrasound (LIPUS) in the management of fractures remains controversial.
The purpose of this study was to assess the feasibility of a definitive trial to determine the effect of LIPUS on functional
and clinical outcomes in tibial fractures managed operatively.
Methods: We conducted a multicenter, concealed, blinded randomized trial of 51 skeletally mature adults with operatively
managed tibial fractures who were treated with either LIPUS or a sham device. All participating centers were located in
Canada and site investigators were orthopedic surgeons specializing in trauma surgery. The goals of our pilot study were
to determine recruitment rates in individual centers, investigators’ ability to adhere to study protocol and data collection
procedures, our ability to achieve close to 100% follow-up rates, and the degree to which patients were compliant with
treatment. Patients were followed for one year and a committee (blinded to allocation) adjudicated all outcomes. The
committee adjudicators were experienced (10 or more years in practice) orthopedic surgeons with formal research training,
specializing in trauma surgery.
Results: Our overall rate of recruitment was approximately 0.8 patients per center per month and site investigators
successfully adhered to the study protocol and procedures. Our rate of follow-up at one year was 84%. Patient compliance,
measured by an internal timer in the study devices, revealed that 39 (76%) of the patients were fully compliant and 12
(24%) demonstrated a greater than 50% compliance. Based on patient feedback regarding excessive questionnaire burden,
we conducted an analysis using data from another tibial fracture trial that revealed the Short Musculoskeletal Function
Assessment (SMFA) dysfunction index offered no important advantages over the SF-36 Physical Component Summary
(PCS) score. No device-related adverse events were reported.
Conclusions: Our pilot study identified key issues that might have rendered a definitive trial unfeasible. By modifying our
protocol to address these challenges we have enhanced the feasibility of a definitive trial to explore the effect of LIPUS on
tibial fracture healing.
Trial registration: The TRUST definitive trial was registered at ClinicalTrials.gov on 21 April 2008 (identifier: NCT00667849).
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Tibial fractures, one of the most common long-bone frac-
tures [1], typically require three to six months before
patients are experiencing only minimal pain and have
returned to their pre-injury functional status. This injury
is associated with substantial loss in productivity and,
moreover, tibial fractures are prone to complications [2-5].
The limited soft tissue envelope surrounding the bone
predisposes tibial fractures to fail to unite (non-unions), a
complication affecting approximately 10% of tibial fracture
patients in North America each year [6]. Non-unions
require surgery to promote fracture healing, surgery that
is associated with its own complications.
One management strategy currently in use to minimize
both fracture healing time and complication rates is low-
intensity pulsed ultrasound (LIPUS). A quarter of respon-
dents to a survey of Canadian orthopedic surgeons and
senior physiotherapy students (n = 77; 77% response rate)
reported use of LIPUS, although 21% of senior physiother-
apy students opined that LIPUS was contraindicated for
fracture healing due to concerns of damaging healing
bone and 25% of surgeons opined that LIPUS had no
effect on bone healing [7]. Of 268 respondents to a survey
of 450 surgeon members of the Canadian Orthopedic
Association (60% response rate), 45% reported use of bone
stimulators for fracture healing in at least some cases,
evenly split between LIPUS and electrical stimulation [8].
Although a number of randomized trials have sug-
gested that LIPUS may improve fracture healing, infer-
ences are limited because of small sample size, risk of
bias, frequent reporting of surrogate outcomes (such as
radiographic healing) but limited attention to patient-
important outcomes (functional recovery), and inconsist-
ent results [9]. Until a large randomized controlled trial
(RCT) is undertaken, the effect of LIPUS on fracture heal-
ing will remain uncertain. The purpose of the current pilot
study was to explore the feasibility of a definitive trial to es-
tablish the role of LIPUS for tibial fracture healing, specif-
ically: to determine recruitment rates in individual centers,
adherence to study protocol and data collection proce-
dures, our ability to achieve close to 100% follow-up rates,
and the degree to which patients complied with treatment.
Availability of data
For this research, full access to the data was not available.
However, the Editors-in-Chief considered it important to




We originally set out to recruit non-operatively managed
tibial fracture patients. After four months we had not en-
rolled a single patient. A survey of 450 Canadian traumasurgeons (60% response rate) revealed a shift in practice
away from non-operative to operative management of tib-
ial fractures in the four years since we had collected the
data on which we based initial recruitment estimates [8].
We therefore revised our eligibility criteria to focus on op-
eratively managed tibial fractures.
Between March 2006 and June 2007 six Canadian
trauma centers recruited 51 patients. All participating
centers were university-affiliated academic trauma hospi-
tals. Site principal investigators were trauma trained
orthopedic surgeons. The human subjects committees
(REB#05-171 - Research Ethics Boards/Institutional Review
Boards) approved the standardized protocol at each partici-
pating site. Specifically, the Hamilton Health Sciences/
McMaster University Research Ethics Board, the University
of Western Ontario Research Ethics Board, the Ottawa
Hospital Research Ethics Board, St. Michael's Hospital
Research Ethics Board, and Sunnybrook Health Sciences
Center Research Ethics Board. We developed, but did not
register, a protocol prior to conduct of the pilot study.
Visually identical active and inactivated (sham) EXO-
GEN 2000+ ultrasound device units with a unit number
were labeled and shipped from the manufacturer (Smith
& Nephew, Memphis, TN) to investigational sites accord-
ing to the randomization plan established by the Methods
and Coordinating Center (CLARITY Methods Center at
McMaster University). The CLARITY Methods Center at
McMaster University was responsible for the traceability
of all investigational devices under this trial.
Participating investigators randomized patients by acces-
sing a 24-hour toll-free remote telephone randomization
system that ensured concealment. Randomization was
stratified by center and by severity of soft-tissue injury
(open or closed) in randomly permuted blocks. Patients
and clinicians were unaware of block sizes. After fracture
fixation with an intramedullary nail, patients were allocated
by a local research coordinator (in a 1:1 ratio) to LIPUS or
a deactivated LIPUS device. The active and placebo-
treatment devices were identical in every way with the
exception of the administration of ultrasound, in that they
had the same visual, tactile, and auditory signals. To ensure
similar perioperative regimens, participating centers stan-
dardized key aspects of pre- and post-operative care. Treat-
ing clinicians were all trauma trained orthopedic surgeons.
Patients, surgeons, and other clinicians, data collectors,
outcome adjudicators, and data analysts were blinded to
treatment allocation until the data analysis was complete
(analysis was done as arms A and B only). We collected
outcome data on patients at discharge and at 6 weeks, 3, 4,
5, 6, 9, and 12 months postoperatively.
Eligibility criteria
Eligible patients were skeletally mature (age 18 years or
older) men or women with an open (Gustillo Grade I-
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able to intramedullary nail fixation. For open fractures,
debridement had to have taken place within 24 hours of
presentation. Inclusion required written informed consent
for trial participation, initiation of treatment with a LIPUS
device within 14 days of intramedullary nailing, and verbal
commitment to comply with the study protocol and
return for all follow-up evaluations.
We excluded patients with: circumferential, open wounds
that precluded placement of an ultrasound device at the
fracture site, general wound care that precluded ultrasound-
skin contact, pilon fractures, tibial fractures that extended
into the knee or ankle joint and required reduction, patho-
logic fractures, bilateral tibial fractures, segmental fractures,
spiral fractures more than 3 inches in length, concomitant
injuries which, in the opinion of the attending surgeon, were
likely to impair function for at least as long as the patient’s
tibial fracture, or tibial fractures that showed less than 25%
cortical contact and more than a 1 cm gap following
intramedullary nail fixation. We also excluded women
who were pregnant or nursing or who planned to
become pregnant over the course of treatment, patients
with active implantable devices such as cardiac pace-
makers, those with cognitive impairment or language
difficulties that might impede the valid completion of
questionnaires, and those who were likely to have prob-
lems with maintaining follow-up. The central adjudication
committee (CAC), including the co-principal investigator
(MB, orthopedic surgeon/methodologist), and two ortho-
pedic surgeons (DS and EHS) adjudicated eligibility.
Interventions
Each patient received a LIPUS device (the EXOGEN
2000+) manufactured by Smith & Nephew, verbal in-
structions on its use, and a booklet containing detailed
instructions. Neither the patient nor the clinical investi-
gator was able to adjust the ultrasound signal. In brief,
after the application of a small amount of ultrasonic
coupling gel to the surface of the ultrasound head, the
patient positioned the treatment head module over the
fracture site and turned on the LIPUS device which
automatically turns off after 20 minutes. The active and
placebo-treatment devices were identical except for the
administration of ultrasound.
Patients self-administered treatment with their device
once daily. Treatment continued until the CAC deter-
mined that the fracture demonstrated radiographic evi-
dence of bridging at all four cortices, or until the 52-week
follow-up visit, whichever occurred first. The EXOGEN
2000+ contains an internal patient use timer which moni-
tors and records use. When the device turns on, it initially
performs a self-test after which it displays the total num-
ber of full treatments completed, then the number of
partial treatments. If the device is removed prior tocompletion of the daily treatment it shuts off and records
the abbreviated treatment time. Patient compliance with
ultrasound treatment was ascertained using the patient
compliance monitor function of the device at each follow-
up office visit until their fracture had healed (defined as
cortical bridging at three of the four cortices). The compli-
ance monitor, however, cannot establish if the device had
been used properly.
Standardization of perioperative treatment
For closed fractures preoperative antibiotic administration
was continued for 24 hours postoperatively. For open frac-
tures preoperative intravenous antibiotic administration
included a cephalosporin and an aminoglycoside that were
continued for 72 hours postoperatively. Irrigation and
debridement of soft tissues and contaminated bone was
repeated as necessary and delayed wound closure, split
thickness skin grafting, or muscle flaps (for grade IIIB
only) occurred only after the initial surgery. For both open
and closed fractures cortical contact of the fracture ends
guided weight bearing. If cortical contact was achieved
patients were instructed to weight bear as tolerated.
Otherwise, patients were instructed to partially weight
bear on the affected limb until performance of a definitive
procedure to achieve contact.
Outcome measures
The goals of our pilot study were to determine recruit-
ment rates in individual centers, adherence to study
protocol and data collection procedures, our ability to
achieve close to 100% follow-up rates, and the degree to
which patients complied with treatment.
The primary effectiveness outcome measure was the
Physical Component Summary (PCS) score of the SF-36.
The SF-36 is a widely accepted, well-validated functional
status measure [10,11]. It is a self-administered, 36-item
questionnaire that measures health-related quality of life
in eight domains. Each domain is scored from 0 (lowest
level) to 100 (highest level). Physical and mental summary
scores can be obtained by aggregating across domains.
The SF-36 has demonstrated good construct validity, high
internal consistency, and high test-retest reliability [12]. In
a previous study, we have shown that three out of four
SF-36 PCS domains are responsive to improvement in
functional recovery in patients with ankle fractures over
a period of one year [13]. The primary safety outcome was
the difference between treatment groups in the proportion
of patients with device-related adverse events and un-
planned secondary procedures related to bone healing and
infection.
Secondary outcomes were radiographic healing, rates of
malunion and nonunion, rates of secondary procedures
(operative and non-operative), the Short Musculoskeletal
Function Assessment (SMFA) dysfunction index, and the
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dated generic utility measure [14-16]). The SMFA is a two
part, 46-item, self-reported health status questionnaire
[17]. One part (the dysfunction index) is designed to
detect changes in the functional status of patients who
have a broad range of musculoskeletal disorders that are
commonly seen in community practices.
We defined a malunion as an angular or rotational
deformity in either the coronal (5 degrees) or sagittal plane
(10 degrees). A non-union was defined as a failure of pro-
gression of radiographic healing in two consecutive months
(after the six-month postoperative visit). The Radiographic
Union Scale for Tibial Fractures (RUST) system assigns a
score to a given set of anteroposterior and lateral radio-
graphs based on the assessment of healing at each of the
four cortices visible on these projections (medial and lat-
eral cortices on the anteroposterior X-ray, anterior and
posterior cortices on the lateral X-ray) [18-20]. Each cortex
receives a score of one point if it is deemed to have a frac-
ture line with no callus, two points if there is callus present
but a fracture line is still visible, and three points if there is
bridging callus with no evidence of a fracture line. The
individual cortical scores are added to give a total for the
set of films, with four being the minimum (indicating the
fracture has definitely not healed) and twelve being the
maximum score (indicating the fracture has definitely
healed). Our CAC judged that a cortex was bridged when
it achieved a RUST score of two or three. Anteroposterior
and lateral radiographs were standardized whenever pos-
sible, with use of the same X-ray machine at each site and
the same exposure settings.
Follow-up
We assessed all outcomes at discharge and at follow-up
visits, with the exception of radiographic healing which
was evaluated until the CAC determined that the bridging
of three cortices had occurred. The CAC, which was
blinded to device allocation, adjudicated all outcomes and
resolved disagreement through discussion. All centers sent
digital photographs of the required radiographs to the
TRUST Methods Center via email. In addition, site coor-
dinators mailed all relevant hospital records. All relevant
blinded patient records (DataFax, Hamilton, Ontario,
Canada; case report forms, chart notes, and radiographs)
were posted on a specially designed, password-protected,
website for adjudication. Disagreements were resolved by
discussion during conference calls. If the adjudicators
could not reach consensus, additional information was
requested from the participating site to clarify areas of un-
certainty. All decisions made by the committee were final.
Sample size
We estimated that 500 patients would be required for a
definitive trial to have a power of 80% (alpha = 0.05,two-tail) to identify a patient-important difference in
absolute SF-36 PCS scores (3 to 5 points) [21] between
treatment and control groups, across a plausible range
in the magnitude of the standard deviation (12 to 14)
[13]. We chose a sample size of 50 patients to assess
feasibility. No interim analyses were planned.
Statistical analyses
Although not the primary objective of our pilot study, we
conducted preliminary repeated measures of variance ana-
lyses, adjusted for treatment, time, fractures-at-risk, base-
line questionnaire scores (only for SF-36 PCS and HUI-III
scores), and three interaction terms: treatment × time,
treatment × fractures-at-risk, and time × fractures-at-risk.
Our analyses followed the intention-to-treat principle and
all patients were analyzed according to the group they
were randomized to. We defined patients with fractures-
at-risk a priori as those presenting with any of the follow-
ing at enrolment: fracture gap (all enrolled fracture gaps
were less than or equal to 1 cm), current smoker, or open
fracture. We set our level of statistical significance at
P <0.05. Our analyses were restricted to those patients
who provided completed questionnaires or radiographs
(complete case analysis). When follow-up time differed
from that specified in the protocol, we used follow-up to
the scheduled time point closest to the actual follow-up. If
two follow-up times were equally near to a single sched-
uled time point, we used data from the earlier follow-up
time.
Funding and role of the sponsor
The Trial to Re-evaluate Ultrasound in the Treatment of
Tibial Fractures (TRUST) was funded under an industry-
partnered research grant from the Canadian Institutes of
Health Research and Smith & Nephew. The Canadian
Institutes of Health Research had no role in the design or
conduct of the study, the collection, analysis, and inter-
pretation of the study, or the preparation, review, or
approval of the manuscript. Smith & Nephew personnel
reviewed initial drafts of the trial protocol and raised many
issues about alternative approaches to study design. Issues
regarding the protocol were resolved through negotiation
between Smith & Nephew and the trial Steering Commit-
tee. Final decisions regarding the protocol and issues that
might arise during the conduct of the trial were the
purview of the trial Steering Committee. The investigators
collected all trial data, with the exception of patient use of
ultrasound devices which was recorded by an internal
timer in each device. A summary of these data were
obtained from Smith & Nephew when study devices were
returned to them (categorized as fully complaint or
partially complaint); the investigators were not provided
with the actual time of usage per patient. Smith &
Nephew had no role in the initial preparation of the
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manuscript and make nonbinding comments and
suggestions.Results
Of the 484 patients who were screened for eligibility, 51
met our study criteria, provided informed consent and
were randomized, for an overall recruitment rate of 10.5%;
37 were closed fractures and 14 open fractures (Figure 1).
Patient enrollment by center was as follows: Hamilton
Health Sciences, Hamilton (n = 22); London Health
Sciences Center, London (n = 12), Queen Elizabeth II
Health Sciences Center, Halifax (n = 7); St. Michael’s
Hospital, Toronto (n = 6); Sunnybrook Hospital, Toronto
(n = 2); and Ottawa Hospital, Ottawa (n = 2).Figure 1 Patient recruitment and follow-up schedule (CONSORT flowAccording to our definitions, we enrolled 28 patients
at high risk of poor outcome and 23 patients at low risk.
Our overall rate of recruitment was approximately 0.8
patients per center, per month; this rate varied by site
from 0.2 to 2 patients per month. We reviewed our 433
ineligible patients and found that many (23%) were
excluded because their tibial shaft fracture extended into
the joint (Figure 1). Patients were predominantly males
who had been injured in a fall (Table 1).
We recorded one stratification error during the pilot
study when a patient with an open fracture received an
ultrasound unit designated for the next patient with a
closed fracture, but all other patients received their
randomly assigned treatment. Trial sites successfully
adhered to protocol and provided full data for all follow-
up visits that patients attended, except for inconsistentdiagram).
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sive respondent burden.
Patient compliance as measured by the ultrasound de-
vice was high, with 39 (76%) registering full compliance
and 12 (24%) registering greater than 50% compliance.
Nine patients stopped treatment early, two started late,
and one patient started late and stopped early. Reasons
provided were forgetting the ultrasound unit while travel-
ing, other forgetfulness, or believing that further treatment
was unnecessary because of perception that the fracture
was healed. One patient initially stopped treatment early
due to losing his coupling gel but resumed once replace-
ment gel was provided. One patient reported applying
ultrasound to both the fracture site and another site,Table 1 Patient characteristics
Sham device LIPUS Total
(n = 28) (n = 23) (n = 51)
Age (years), mean (SD) 39.6 (13.6) 39.0 (13.6) 39.3 (13.5)
Females, n(%) 7 (25.0) 5 (21.7) 12 (23.5)
Mechanism of injury, n(%)
MVA, driver or passenger 4 (14.3) 1 (4.3) 5 (9.8)
MVA, pedestrian 1 (3.6) 1 (4.3) 2 (3.9)
Motorcycle accident 3 (10.7) 4 (17.4) 7 (13.7)
Crush injury 3 (10.7) 4 (17.4) 7 (13.7)
Fall 10 (35.7) 9 (39.1) 19 (37.3)
Twist 1 (3.6) 1 (4.3) 2 (3.9)
Direct trauma, blunt 2 (7.1) 2 (8.7) 4 (7.8)
Recreational vehicle injury 3 (10.7) 1 (4.3) 4 (7.8)
Hockey injury 1 (3.6) 0 (0.0) 1 (2.0)
Diabetic, n(%) 1 (3.6) 0 (0.0) 1 (2.0)
Current smoker, n(%) 10 (35.7) 6 (26.1) 16 (31.4)
Type of fracture, n(%)
Open 9 (32.1) 5 (21.7) 14 (27.5)
Closed 19 (67.9) 18 (78.3) 37 (72.5)
AO Class, n(%)
A 13 (46.4) 11 (47.8) 24 (47.1)
B 9 (32.1) 6 (26.1) 15 (29.4)
C 6 (21.4) 6 (26.1) 12 (23.5)
Any comorbidity1, n(%) 3 (10.7) 1 (4.3) 4 (7.8)
Post-surgical fracture gap, n(%)
Any gap (restricted to ≤1 cm) 6 (21.4) 0 (0.0) 6 (11.8)
No gap 22 (78.6) 23 (100.0) 45 (88.2)
Fracture-at-risk2, n(%) 21 (75.0) 12 (52.2) 33 (64.7)
1diabetes, renal disease, vascular disease or insufficiency, thrombophlebitis,
alcoholism, or drug abuse.
2open fracture, current smoker, comorbidity, AO class C, or any fracture
gap ≤1 cm.
AO: Arbeitsgemeinschaft für Osteosynthesefragen; LIPUS: low-intensity pulsed
ultrasound; MVA: motor vehicle accident; SD: standard deviation; TRUST: Trial
to Re-evaluate Ultrasound in the Treatment of Tibial Fractures.which was corrected by instruction from his site’s research
coordinator.
Of our 51 enrolled patients, 1 withdrew consent after
6 weeks following advice from his physiotherapist that the
ultrasound device would damage healing bone, and 1 was
lost to follow-up after his fracture was declared healed and
he left the country; another 6 patients failed to return for
assessment at 1 year for unknown reasons. As such, we
had 16% of enrolled patients (8 of 51) lost to follow-up.
Overall, we successfully completed 82% of all follow-up
visits; follow-up rates varied by site from 43% to 98%.
Repeated measures of variance analysis found that
treatment with LIPUS versus sham therapy was not sig-
nificantly associated with improvement in SF-36 PCS
scores (time × treatment interaction, P = 0.27), HUI-III
scores (time × treatment interaction, P = 0.31), or RUST
scores (time × treatment interaction, P = 0.53). Patient
with fractures-at-risk demonstrated worse outcomes
across all three measures. The adjusted means for SF-36
PSC, HUI-III, and RUST scores at each time point, and
a breakdown by fracture risk status are provided else-
where (see Additional files 1, 2 and 3).
There were 50 reported adverse events in the pilot
study. Eight were reported at the time of enrolment and
before the administration of the first treatment. The
remaining 42 adverse events included: 6 wound infections
(3 in the same patient), 6 hardware removals to alleviate
discomfort, 6 irrigations and debridements due to infection
(2 in same patient), 4 hardware removals for dynamization,
2 recurrences of pneumonia originally acquired prior to
enrolment (in the same patient), 1 hospitalization for deep
vein thrombosis and pulmonary embolism, 1 intramedul-
lary nail loosening suggestive of a deep infection, and 1
case of neurapraxia (see Additional file 4). No site investi-
gators reported any adverse events that they believed to be
associated with the study treatment.
Discussion
Our pilot study demonstrated that a definitive trial to
establish the effect of LIPUS on tibial fracture healing is
feasible. Specifically, we determined recruitment rates in
individual centers, found excellent adherence to study
protocol and data collection procedures among centers,
achieved an acceptable follow-up rate (84%), and estab-
lished that most patients are compliant with treatment.
Our pilot study revealed highly variable recruitment
rates among individual trauma centers. Most patients
(89.5%) presenting with tibial fractures that we screened
were not eligible for enrolment, often due to fractures
extending into the joint. We successfully completed 82%
of follow-up visits, and adherence to study protocol and
data collection procedures were excellent with the excep-
tion of completion of the SMFA. Our analysis of our pri-
mary outcome and certain secondary outcome measures
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from our definitive trial, which is in progress, will be
required to confirm or refute our preliminary findings.
Our findings that patients who smoke, those with open
tibial fractures, and those with a fracture gap demonstrate
worse outcomes as measured by SF-36 PCS, HUI-III, and
RUST scores suggest that our definitive trial should
consider fractures-at-risk for subgroup analyses.
On consultation, both the manufacturers of the Exogen
ultrasound bone stimulator device and our consultant
trauma surgeons opined that tibial fractures extending
into the joint would respond to LIPUS treatment in a
similar way to currently eligible patients. Accordingly, for
our definitive trial we have expanded our eligibility criteria
to include tibial shaft fractures that extend into the joint
and do not require reduction. Given our recruitment data,
we concluded that our definitive trial should engage 25
trauma centers for patient enrolment, and that we should
set a priori recruitment rate criteria for centers to remain
actively recruiting in the TRUST trial; specifically, all
participating sites must enroll at least one patient every
four months.
To explore if the data from the SMFA justified the
respondent burden, we analyzed data from the recently
completed SPRINT trial [22], which also studied opera-
tively managed tibial shaft fractures (n = 1339) and admin-
istered both the SF-36 and SMFA. Both instruments
proved responsive, instrument scores were highly corre-
lated (correlation at 1-year post surgery was -0.80 (95%
confidence interval = -0.83 to -0.77)), and the difference in
standardized change scores between instruments was not
significant (standardized response mean of 0.95 versus
1.00, P = 0.16) [23]. Given these results, we concluded that
the additional information from administering both ques-
tionnaires was insufficient to justify the respondent
burden. The far more extensive use of the SF-36, its more
extensive validation, and its ability to compare to other
populations dictates the SF-36 as the instrument of choice.
To further improve patient compliance in the definitive
TRUST trial we are providing each TRUST site with extra
coupling gel, informing all patients at enrolment that
replacement gel is available, and instructing all patients at
enrolment that their LIPUS device is to be used only at
the indicated fracture site. The ultrasound devices to be
used in the definitive TRUST trial have been upgraded to
reduce weight and size and thereby improve portability.
Site research coordinators will reinforce the importance of
compliance with the prescribed treatment administration
at each patient follow-up visit.
To improve the rate of follow-up in the definitive
TRUST trial, enrolled patients’ physiotherapists will be
sent a letter outlining the current evidence about treat-
ment of fractures with LIPUS and the safety of this modal-
ity. All site research coordinators and investigators will beinformed that patients who leave the country, or migrate
within the country, can be followed up using telephone
administration of outcome measures. Finally, we will pro-
vide financial compensation to patients to cover travel
costs for follow-up visits.
Conclusions
Our pilot study identified key issues that might have
rendered a definitive trial unfeasible. By switching to an
operatively managed population, broadening our eligibility
criteria, reducing the number of study questionnaires, and
taking additional steps to encourage higher rates of patient
compliance and follow-up, we have enhanced the feasibil-
ity of a definitive trial to explore the effect of LIPUS on
tibial fracture healing. Our results illustrate the potential
and value of pilot studies before embarking on definitive
orthopedic trials.
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Additional file 1: Adjusted Mean SF-36 PCS Scores. Description of
data: A comparison of adjusted mean SF-36 PCS scores for the treatment
and control groups, at each follow-up time.
Additional file 2: Adjusted Mean HUI-III Scores. Description of data: A
comparison of adjusted mean HUI-III scores for the treatment and control
groups, at each follow-up time.
Additional file 3: Adjusted Mean RUST Scores. Description of data: A
comparison of adjusted mean RUST scores for the treatment and control
groups, at each follow-up time.
Additional file 4: Adverse events. Description of data: Adverse events
reported in both treatment arms.
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